Nervgen Pharma Corp (NGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2001 | 09-2001 | 06-2001 | 03-2001 | 12-2000 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -32,500 | -25,040 | -18,020 | -6,270 | -18,280 |
| Depreciation Amortization | 3,470 | 2,510 | 1,540 | 760 | 3,020 |
| Other Working Capital | -5,770 | -5,540 | -5,800 | -2,730 | -4,490 |
| Other Operating Activity | 1,820 | 2,170 | 5,220 | 120 | 450 |
| Operating Cash Flow | $-32,980 | $-25,900 | $-17,060 | $-8,120 | $-19,300 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -650 | -50 | -30 | -5 | -50 |
| Other Investing Activity | -16,400 | -19,750 | -17,550 | -10,545 | -44,470 |
| Investing Cash Flow | $-17,050 | $-19,800 | $-17,580 | $-10,550 | $-44,520 |
| Cash Flows From Financing Activities | |||||
| Other Financing Activity | 5,150 | 4,440 | -260 | -220 | 78,130 |
| Financing Cash Flow | $5,150 | $4,440 | $-260 | $-220 | $78,130 |
| Exchange Rate Effect | 5 | 180 | 0 | 0 | 0 |
| Beginning Cash Position | 55,330 | 55,330 | 55,330 | 55,330 | 41,020 |
| End Cash Position | 10,450 | 14,240 | 20,410 | 36,420 | 55,330 |
| Net Cash Flow | $-44,870 | $-41,080 | $-34,910 | $-18,900 | $14,300 |
| Free Cash Flow | |||||
| Operating Cash Flow | -32,980 | -25,900 | -17,060 | -8,120 | -19,300 |
| Free Cash Flow | -32,980 | -25,900 | -17,060 | -8,120 | -19,300 |